SHCBP1 drives tumor progression in triple-negative breast cancer

SHCBP1 drives tumor progression in triple-negative breast cancer

BackgroundsTriple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype. The limited treatment options underscore the urgent need to explore novel molecular targets to combat TNBC progression. This study investigates the oncogenic functions of SHCBP1 in TNBC.Materials an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Huiling Wang, Huijuan Dai, Liheng Zhou, Yanping Lin, Wenjin Yin, Jingsong Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Oncology
Subjects:	SHCBP1 single-cell RNA-seq triple negative breast cancer proliferation migration
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1587236/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Plasma exosomes in insulin resistant obesity exacerbate progression of triple negative breast cancer
by: Pablo Llévenes, et al.
Published: (2025-07-01)

Blood mononuclear cell molecular landscape associated with tumor progression in triple-negative breast cancer
by: M. R. Patysheva, et al.
Published: (2023-11-01)

Immune microenvironment and prognostic genes of triple-negative breast cancer in the context of transcriptome and single-cell sequencing
by: Xiangqin Huang, et al.
Published: (2025-08-01)

Triple-negative breast cancer: Pattern of recurrence and survival outcomes
by: Shyny Reddy Chintalapani, et al.
Published: (2019-01-01)

Results of combination treatment for triple-negative breast cancer
by: M. A. Sekundova, et al.
Published: (2014-07-01)

Molecular genetic predictors of progression of triple negative breast cancer
by: I. S. Panchenko, et al.
Published: (2025-03-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

Caveolin-1 in Tumour Cells is Predominately Expressed in the Basal Subtype of Triple-Negative Breast Carcinoma
by: Savelina Popovska, et al.
Published: (2014-11-01)

Therapeutic limitations of oncolytic VSVd51-mediated miR-199a-5p delivery in triple negative breast cancer models
by: Guillaume St-Cyr, et al.
Published: (2025-05-01)

Leptomeningeal metastasis in triple-negative breast cancer: a retrospective study
by: Yun-Yi Wang, et al.
Published: (2025-08-01)

The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer
by: Chikako Funasaka, et al.
Published: (2025-01-01)

Central nervous system relapse in triple-negative breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy: A retrospective cohort analysis
by: Gabriel Berlingieri Polho, et al.
Published: (2025-10-01)

Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies
by: Belén Sierro-Martínez, et al.
Published: (2025-08-01)

LRPPRC confers enhanced oxidative phosphorylation metabolism in triple-negative breast cancer and represents a therapeutic target
by: Qiqi Xue, et al.
Published: (2025-03-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer
by: Cheng Hyun Lee, et al.
Published: (2025-07-01)

Chemotherapeutic drug scavenger-based combination therapy toward treating triple-negative breast cancer
by: Qingqing Yin, et al.
Published: (2025-07-01)

Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple‐Negative Breast Cancer
by: Xinran Wang, et al.
Published: (2025-05-01)

Analysis of survival differences in advanced triple-negative breast cancer: a real-world study
by: Jun-Sheng Zheng, et al.
Published: (2025-08-01)

Intratumoral microbiota-aided fusion radiomics model for predicting tumor response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer
by: Yilin Chen, et al.
Published: (2025-03-01)

Clinical case of torpid course of metastatic triple negative breast cancer
by: E. P. Kulikov, et al.
Published: (2022-03-01)

Mitogen‐activated protein kinase activity drives cell trajectories in colorectal cancer
by: Florian Uhlitz, et al.
Published: (2021-08-01)

Pharmacological mechanisms of berberine against triple negative breast cancer: Integration of network pharmacology and experimental validation
by: Tian Qin, et al.
Published: (2025-08-01)

Metformin-Based Combination Approaches for Triple-Negative Breast Cancer
by: Zaid Sirhan, et al.
Published: (2025-04-01)

Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study
by: Beate Vajen, et al.
Published: (2025-05-01)

Fundamental knowledge and research regarding the role of immunity in triple-negative breast cancer from 2014–2024: A bibliometric analysis
by: Xudong Li, et al.
Published: (2025-12-01)

Size matters: a review of the challenges in and importance of multimodal approaches to the management of patients with small, node-negative, triple-negative breast cancer
by: Vishnu Prasath, et al.
Published: (2025-07-01)

THEM6 modulates carboplatin sensitivity by regulating ferroptosis through FDFT1 in triple-negative breast cancer
by: Yuexiang Zeng, et al.
Published: (2025-07-01)

Knowledge mapping of ultrasound technology and triple-negative breast cancer: a visual and bibliometric analysis
by: Yonglin Wan, et al.
Published: (2025-07-01)

Effect of body mass index on clinical and morphological characteristics of triple negative breast cancer
by: I. B. Schepotin, et al.
Published: (2014-07-01)

Deep learning for survival prediction in triple-negative breast cancer: development and validation in real-world cohorts
by: Yiyue Xu, et al.
Published: (2025-08-01)

CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms
by: Liu Haiyan, et al.
Published: (2025-08-01)

Dual-ferroptosis induction-based microneedle patches for enhanced chemodynamic/photothermal combination therapy against triple-negative breast cancer
by: Yujie Wang, et al.
Published: (2025-08-01)

Natural Products as Novel Therapeutic Agents for Triple-Negative Breast Cancer: Current Evidence, Mechanisms, Challenges, and Opportunities
by: Qingzhou Li, et al.
Published: (2025-03-01)

Correction: Analysis of prognostic factors and nomogram construction for postoperative survival of triple-negative breast cancer
by: Chenxi Wang, et al.
Published: (2025-08-01)

A Preliminary Study on the Therapeutic Role of γδT Cells in Triple‐Negative Breast Cancer
by: Shi Qiu, et al.
Published: (2025-08-01)

Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial
by: Vinod K. Ramani, et al.
Published: (2025-08-01)

Oral microbiome components predict response to neoadjuvant chemotherapy in triple-negative breast cancer patients
by: Xiaoyan Fu, et al.
Published: (2025-07-01)

The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis
by: Eva L. Claassens, et al.
Published: (2025-04-01)

EPHA2 promotes triple-negative breast cancer progression by suppressing pyroptosis via the AKT/PI3K/mTOR pathway
by: Xiaoying Huang, et al.
Published: (2025-08-01)